United Therapeutics (UTHR) is back in focus after reporting first quarter results with lower year-on-year revenue and a meaningful earnings miss versus analyst expectations, which weighed on investor confidence and pressured the stock.

Beyond the weak first quarter, United Therapeutics’ share price has drifted, with a 30 day share price return of a 3.24% decline and a modest 3.28% gain over 90 days, while a 1 year total shareholder return of 92.33% highlights how strong the longer term performance has been.

If you are reassessing biotech exposure after United Therapeutics’ latest update, it could be a good time to broaden your watchlist with 38 healthcare AI stocks.

So with United Therapeutics delivering weak first quarter results but still carrying a strong longer term track record, is the recent pullback hinting at an undervalued stock, or is the market already pricing in future growth?

Most Popular Narrative: 17.3% Undervalued

With United Therapeutics last closing at $550.01 against a narrative fair value of $665.23, the current setup hinges on how investors view its long term pulmonary and organ platform story.

The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine. These areas can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.

Curious what earnings, revenue growth, and margin profile are baked into that fair value for United Therapeutics? The narrative leans on compound growth, richer margins, and a future valuation multiple that together sketch a very specific earnings path. The details behind those assumptions are where the story really gets interesting.

Result: Fair Value of $665.23 (UNDERVALUED)

However, United Therapeutics still carries key risks, including potential setbacks in the TETON or ADVANCE OUTCOMES trials, as well as pricing or reimbursement pressure on its pulmonary portfolio that could challenge this narrative.

Another View on United Therapeutics Valuation

While the narrative fair value suggests United Therapeutics is 17.3% undervalued, the current P/E of 18.1x paints a different picture. It sits above the US biotech industry at 16.8x, yet below peers at 19.4x and the fair ratio of 24.1x. This raises the question of whether the risk is skewed toward re-rating or de-rating next.

Next Steps

If this mix of optimism and caution around United Therapeutics leaves you unsure, move quickly to review the underlying data, refine your own view, and then compare those findings with the 4 key rewards

Looking for more investment ideas beyond United Therapeutics?

Once you have a clear view on United Therapeutics, do not stop there. Broaden your opportunity set with focused screeners that surface stocks matching your preferred profile.

• Target higher income potential by reviewing 7 dividend fortresses that combine strong yields with disciplined payout profiles.
• Hunt for mispriced opportunities by scanning 44 high quality undervalued stocks where fundamentals and valuation work in your favor.
• Prioritize capital preservation by filtering for 70 resilient stocks with low risk scores that aim to balance return potential with more measured risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.